Lyell Immunopharma, Inc.
LYEL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001806952
In the last 90 days, Lyell Immunopharma, Inc. insiders filed 0 open-market purchases and 10 sales; 87 institutions reported holding it in 13F filings for Q2 2026, worth $178.0M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $211.3K in total
- 10
- 13F holdersQ2 2026, +14 vs. previous quarter
- 87
- 13F valueReported value at the end of Q2 2026
- $178.0M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding LYEL, Q2 2026
No superinvestor reported holding LYEL at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Lyell Immunopharma, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 10, 2026 (view filing)7:37 PM ET | Sep 10 | Same day | Shook DavidChief Medical Officer | SSale | −500 | $12.70 | −$6.35K | −2.4%20.4K after | |
| Aug 25, 2026 (view filing)4:06 PM ET | Aug 21 | 4 days | Seely LynnPresident and CEO | SSale | −9.59K | $15.54 | −$149.0K | −13.0%63.9K after | |
| Aug 25, 2026 (view filing)4:05 PM ET | Aug 21 | 4 days | Hill Stephen J.Chief Operating Officer | SSale | −989 | $15.54 | −$15.4K | −5.6%16.8K after | |
| Aug 25, 2026 (view filing)4:03 PM ET | Aug 21 | 4 days | Lee Gary K.Chief Scientific Officer | SSale | −1.46K | $15.54 | −$22.6K | −8.2%16.2K after | |
| Aug 11, 2026 (view filing)4:21 PM ET | Aug 10 | 1 day | Bulis Veronica SanchezVP, Corporate Controller | SSale | −621 | $14.34 | −$8.91K | −4.0%14.8K after | |
| Aug 11, 2026 (view filing)4:20 PM ET | Aug 10 | 1 day | Lee Gary K.Chief Scientific Officer | SSale | −131 | $14.34 | −$1.88K | −0.7%17.7K after | |
| Aug 11, 2026 (view filing)4:18 PM ET | Aug 10 | 1 day | Hill Stephen J.Chief Operating Officer | SSale | −89 | $14.34 | −$1.28K | −0.5%17.8K after | |
| Aug 11, 2026 (view filing)4:07 PM ET | Aug 10 | 1 day | Seely LynnPresident and CEO | SSale | −390 | $14.34 | −$5.59K | −0.5%73.5K after | |
| Jul 20, 2026 (view filing)2:55 PM ET | Jul 17 | 3 days | Innovative Cellular Therapeutics Holdings Ltd10% Owner | SSale | −10 | $13.70 | −$137 | 0.0%2.86M after | 10b5-1 |
| Jul 17, 2026 (view filing)9:45 PM ET | Jul 16 | 1 day | Innovative Cellular Therapeutics Holdings Ltd10% Owner | SSale | −10 | $13.73 | −$137.3 | 0.0%2.86M after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Lyell Immunopharma, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| ARCH Venture Management, LLC | 3,247,162 | $45.5M | 4.14% | 00.0% | Unchanged |
| GSK plc | 1,512,659 | $21.3M | 3.53% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 786,774 | $11.1M | 0.00% | +68,619+9.6% | Added |
| Orland Properties Ltd | 754,698 | $10.6M | 5.25% | 00.0% | Unchanged |
| BlackRock, Inc. | 724,342 | $10.2M | 0.00% | +532,522+277.6% | Added |
| Decheng Capital LLC | 692,050 | $9.72M | 1.33% | 00.0% | Unchanged |
| Almitas Capital LLC | 581,407 | $8.17M | 1.96% | +3,600+0.6% | Added |
| Foresite Capital Management V, LLC | 476,386 | $6.69M | 1.85% | −692−0.1% | Reduced |
| Millennium Management LLC | 367,473 | $5.16M | 0.00% | −91,432−19.9% | Reduced |
| Opaleye Management Inc. | 344,025 | $4.83M | 0.44% | +264,928+334.9% | Added |